Nestlé will take full ownership of Aimmune Therapeutics, the developer of FDA approved peanut allergy drug Palforzia, by acquiring the remaining stake of 74.4% in the latter for about $2 billion. The deal is expected to help the Swiss conglomerate’s subsidiary Nestlé Health Science and Aimmune Therapeutics to create a global leader in the prevention […]
Aimmune Therapeutics said that the first patients in the US are being treated with the recently FDA approved peanut allergy drug PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp]. The California-based biopharma company said that specialty pharmacies are shipping initial dosing kits of the new peanut allergy drug to allergists for in-office administration to their peanut-allergic patients […]